Johannes Popow

Boehringer Ingelheim (Germany) — Germany

Medicine · Health Sciences

16h-index2.5kcitations59works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(21), Protein Degradation and Inhibitors(17), Biochemical and Molecular Research(17), Lung Cancer Treatments and Mutations(13), Microtubule and mitosis dynamics(12)

Publications59 total

Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles
Journal of the American Chemical Society·2025· 1 citedOpen Access
Combining BET inhibition with SMAC mimetics restricts tumor growth and triggers immune surveillance in preclinical cancer models
Cell Reports Medicine·2025· 1 citedOpen Access
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-loaded KRAS(on) Alleles
2025Open Access
Supplementary Figure 1 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 8 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Data from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 6 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 2 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 10 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 4 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Tables 1-5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 7 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 1 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 2 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 9 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
2025Open Access
Supplementary Data Table 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
2025Open Access
page 1 of 3Next →

Frequent Co-authors

Mark Pearson(31), Daniel Gerlach(27), Norbert Kraut(26), Jesse Lipp(18), Dorothea Rudolph(17), Michael Gmachl(15), Antonio Tedeschi(15), Francesca Rocchetti(15), Ralph A. Neumüller(14), Fiorella Schischlik(14), Anke Baum(13), Florian Ebner(13), Matthew G. Rees(13), Jennifer A. Roth(13), Matthias Samwer(13), Fiona Spreitzer(12), Birgit Wilding(12), Antonia Geyer(12), Valeria Santoro(12), Andrew S. Boghossian(12)